Impact of subsequent post-discontinuation immunotherapy on overall survival in patients with unresectable, stage III NSCLC from PACIFIC

被引：0
|
作者：
Ouwens, M. [1 ,2 ]
Darilay, A. [2 ]
Zhang, Y. [2 ]
Mukhopadhyay, P. [2 ]
Mann, H. [3 ]
Ryan, J. [3 ]
Dennis, P. A. [2 ]
机构：
[1] AstraZeneca, Gothenburg, Sweden
[2] AstraZeneca, Gaithersburg, MD USA
[3] AstraZeneca, Cambridge, England
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
83O
引用
收藏
页码：31 / 31
页数：1
相关论文
共 50 条
  • [1] Impact of subsequent post-discontinuation immunotherapy on overall survival in patients with unresectable, stage III NSCLC from PACIFIC
    Fischer, J. R.
    Schulz, C.
    Laack, E.
    Wolff, T.
    Rueckert, A.
    Reck, M.
    Faehling, M.
    de Wit, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 209 - 209
  • [2] First Subsequent Treatment After Discontinuation of Durvalumab in Unresectable, Stage III NSCLC Patients from PACIFIC
    Faehling, Martin
    Planchard, David
    Cho, Byoung Chul
    Gray, Jhanelle Elaine
    Paz-Ares, Luis G.
    Ozguroglu, Mustafa
    Villegas, Augusto E.
    Daniels, Davey B.
    Vicente, David
    Murakami, Shuji
    Hui, Rina
    Kurata, Takayasu
    Chiappori, Alberto
    Lee, Ki Hyeong
    Gu, Yu
    Wadsworth, Catherine
    Dennis, Phillip A.
    Antonia, Scott Joseph
    de Wit, Maike
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 120 - 120
  • [3] First subsequent treatment after discontinuation of durvalumab in unresectable, stage III NSCLC patients from PACIFIC.
    Planchard, David
    Cho, Byoung Chul
    Gray, Jhanelle Elaine
    Paz-Ares, Luis G.
    Ozguroglu, Mustafa
    Villegas, Augusto E.
    Daniel, Davey B.
    Vicente, David
    Murakami, Shuji
    Hui, Rina
    Kurata, Takayasu
    Chiappori, Alberto
    Lee, Ki Hyeong
    De Wit, Maike
    Gu, Yu
    Wadsworth, Catherine
    Dennis, Phillip A.
    Antonia, Scott Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non-Small Cell Lung Cancer from the PACIFIC Study
    Ouwens, Mario
    Darilay, Annie
    Zhang, Yiduo
    Mukhopadhyay, Pralay
    Mann, Helen
    Ryan, James
    Dennis, Phillip A.
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2021, 95
  • [5] Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R
    Filippi, A. R.
    Bar, J.
    Chouaid, C.
    Christoph, D. C.
    Field, J. K.
    Fietkau, R.
    Garassino, M. C.
    Garrido, P.
    Haakensen, V. D.
    Kao, S.
    Markman, B.
    Mcdonald, F.
    Mornex, F.
    Moskovitz, M.
    Peters, S.
    Sibille, A.
    Siva, S.
    Heuvel, M. van den
    Vercauter, P.
    Anand, S.
    Chander, P.
    Licour, M.
    Lima, A. R. de
    Qiao, Y.
    Girard, N.
    ESMO OPEN, 2024, 9 (06)
  • [6] Impact of Adjuvant Immunotherapy on Overall Survival in a Contemporary Cohort of Patients with Stage III Melanoma
    Cimarron E. Sharon
    Gabriella N. Tortorello
    Kevin Ma
    Andrew J. Sinnamon
    Tara C. Mitchell
    Giorgos C. Karakousis
    John T. Miura
    Annals of Surgical Oncology, 2023, 30 : 5329 - 5332
  • [7] Impact of Adjuvant Immunotherapy on Overall Survival in a Contemporary Cohort of Patients with Stage III Melanoma
    Sharon, Cimarron E. E.
    Tortorello, Gabriella N. N.
    Ma, Kevin
    Sinnamon, Andrew J. J.
    Mitchell, Tara C. C.
    Karakousis, Giorgos C. C.
    Miura, John T. T.
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (09) : 5329 - 5332
  • [8] PACIFIC: Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC
    Raben, D.
    Faivre-Finn, C.
    Spigel, D.
    Daniel, D.
    Villegas, A.
    Vincente, D.
    Hui, R.
    Carpeno, J. de Castro
    Murakami, S.
    Paz-Ares, L.
    Ozguroglu, M.
    Kurata, T.
    Chiappori, A.
    Lee, K. H.
    de Wit, M.
    Poole, L.
    Wadsworth, C.
    Dennis, P. A.
    Antonia, S. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (05): : 1607 - 1608
  • [9] Impact of chemoradiotherapy on the survival of patients with stage III NSCLC
    Basto, R.
    Correia Magalhaes, J.
    de Sousa, M. J. P.
    Monteiro, J. C.
    Domingues, I.
    Jesus, E.
    Sousa, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S743 - S743
  • [10] Survival Score for Predicting Overall Survival of Multimodally Treated Patients with Stage III NSCLC
    Taugner, J.
    Kaesmann, L.
    Eze, C.
    Dantes, M.
    Roengvoraphoj, O.
    Gennen, K.
    Karin, M.
    Tufman, A.
    Belka, C.
    Manapov, F.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 : S142 - S143
12345